Insulet Corp. (PODD) Cuts Q4, FY14 Revs Outlook

Insulet Corp. (NASDAQ: PODD) updated fourth quarter 2014 guidance to reflect a delay in shipments of its non-insulin drug delivery products from the fourth quarter of 2014 to the first quarter of 2015.

As a result of this delay, for the fourth quarter of 2014, the Company expects that revenue will be in the range of $71 to $73 million, versus prior estimates of $76 to $81 million. The Company expects growth in the fourth quarter of 2014 of approximately 10% from its U.S. direct diabetes business and approximately 40% from its international diabetes business compared to the same period last year. For the year ended December 31, 2014, the Company now estimates revenues to be in the range of $287 to $289 million, versus prior estimates of $292 to $297 million.

*** The Street sees Q4 revs of $79.5 million and FY14 EPS of $296 million.

In 2015, Insulet expects that revenues associated with non-insulin drug delivery products will be in the range of $10 to $20 million.

As previously announced, Insulet will be participating in the 33rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco. Management is scheduled to present an overview of the Company on Wednesday, January 14, 2015 at 1:30 p.m. Pacific Time.

You May Also Be Interested In

• Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); Power Solutions International, Inc. (NASDAQ: PSIX); and PROCEPT BioRobotics Corporation (
• Rapid7, Inc. (RPD) Tops Q2 EPS by 9c; offers guidance
• Simon Property Group (SPG) Misses Q2 EPS by 12c; offers guidance